In the wake of disappointing full-year financial results, shares in Australian Clinical Labs (ASX:ACL) have tumbled by a substantial 14.1%, sinking to a record low of A$2.765.

The pathology services provider reported a statutory profit attributable of A$35.9 million, indicating a sharp decline of 79.9%.

Also, the company posted a statutory total revenue from ordinary activities amounting to A$697.1 million, which is a 30.0% decrease from the previous year.

This has led to the company’s greatest intraday fall ever recorded.

Trading was robust, with roughly 2.2 million shares changing hands, exceedingly bypassing the 30-day average trading volume of 431,664 shares.

The company’s stock was previously up by 8.1% year-to-date as of its last close.

Australian Clinical Labs is a provider of pathology services.